دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Distal versus conventional radial access for coronary angiography and intervention: Design and rationale of DISCO RADIAL study$
AdelAminianMDaGregory A.SguegliaMDPhDbMarcusWiemerMDcGabriele LuigiGaspariniMDdJoelleKeferMDPhDeZoltanRuzsaMDPhDfgMaarten A.H.van LeeuwenMDPhDhBertVandelooMDiClaudiuUngureanuMDjSaskoKedevMDPhDkJuan FIglesiasMDPhDlGregorLeibundgutMDmKarimRatibMBChBnIvoBernatMDPhDoIreneBarriocanalMScpVladimirBorovicaninMDpShigeruSaitoMDPhDq
doi : 10.1016/j.ahj.2021.10.180
Volume 244, February 2022, Pages 19-30
Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial
DongHuangM.DaHongxianWuM.DaJunZhouM.DbXinZhongM.DaWeiGaoM.DaYuanjiMaM.DaJuyingQianM.DaJunboGeM.Da
doi : 10.1016/j.ahj.2021.11.005
Volume 244, February 2022, Pages 86-93
Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF)
LamaGhaziMDaNihar R.DesaiMD, MPHabMichaelSimonovMDaYuYamamotoMSaKyle D.O'ConnorBSaRalph J.RielloPharmDaJoannaHuangPharmDdeTemitopeOlufadePhD, MPHdeJamesMcDermottPhDdeSilvio E.InzucchiMDcEric J.VelazquezMDbF. PerryWilsonMD, MSCEabTariqAhmadMD, MPHab
doi : 10.1016/j.ahj.2021.11.010
Volume 244, February 2022, Pages 107-115
Heart failure with reduced ejection fraction (HFrEF) is one of the most common chronic illnesses in the United States and carries significant risk of morbidity and mortality. Use of guideline-directed medical therapy (GDMT) for patients with HFrEF has been shown to dramatically improve outcomes, but adoption of these treatments remains generally low. Possible explanations for poor GDMT uptake include lack of knowledge about recommended management strategies and provider reluctance due to uncertainties regarding application of said guidelines to real-world practice. One way to overcome these barriers is by harnessing the electronic health record (EHR) to create patient-centered "best practice alerts" (BPAs) that can guide clinicians to prescribe appropriate medical therapies. If found to be effective, these low-cost interventions can be rapidly applied across large integrated healthcare systems. The PRagmatic Trial Of Messaging to Providers about Treatment of Heart Failure (PROMPT-HF) trial is a pragmatic, cluster randomized controlled trial designed to test the hypothesis that tailored and timely alerting of recommended GDMT in heart failure (HF) will result in greater adherence to guidelines when compared with usual care. PROMPT-HF has completed enrollment of 1,310 ambulatory patients with HFrEF cared for by 100 providers who were randomized to receive a BPA vs usual care. The BPA alerted providers to GDMT recommended for their patients and displayed current left ventricular ejection fraction (LVEF) along with the most recent blood pressure, heart rate, serum potassium and creatinine levels, and estimated glomerular filtration rate. It also linked to an order set customized to the patient that suggests medications within each GDMT class not already prescribed. Our goal is to examine whether tailored EHR-based alerting for outpatients with HFrEF will lead to higher rates of GDMT at 30 days post randomization when compared with usual care. Additionally, we are assessing clinical outcomes such as hospital readmissions and death between the alert versus usual care group.
Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?
Khadijah K.BreathettMD, MSaHaolinXuMSbNancy K.SweitzerMD, PhDaElizabethCalhounPhD, MedcRoland A.MatsouakaPhDbClyde W.YancyMD, MScdGregg C.FonarowMDeAdam D.DeVoreMD, MHSfDeepak L.BhattMD, MPHgPamela N.PetersonMD, MSPHhi
doi : 10.1016/j.ahj.2021.11.011
Volume 244, February 2022, Pages 135-148
Whole genome sequencing in transposition of the great arteries and associations with clinically relevant heart, brain and laterality genes
Gillian M.BluePhDabMaukMekelMDcDebjaniDasPhDdMichaelTroupBCST(adv)(hons)dEmmaRathPhDdeEddieIpBScdMikhailGudkovB.Eng(Hon)dGopinathPerumalMD, FRCS, CthaRichard P.HarveyPhDdefGary F.ShollerMBBS, FRACPabJozefGeczPhD, FAA, FAHMS, FFSc(RCPA)gEdwin P.KirkMBBS, PhD, FRACP, FRCPAhiJinfenLiuMDjEleniGiannoulatouDPhilde*HaifaHongMD, PhDj⁎Sally L.DunwoodiePhDde*David S.WinlawMBBS, MD, FRACSabdek*
doi : 10.1016/j.ahj.2021.10.185
Volume 244, February 2022, Pages 1-13
Electrical cardioversion of atrial fibrillation and the risk of brady-arrhythmic events
Peter VibeRasmussenMDaPaulBlanchePhDabFrederikDalgaardMD, PhDaGunnar HilmarGislasonMD, PhDacdChristianTorp-PedersenMD, DMScefJacobTønnesenMDaMartin H.RuwaldMD, PhDaJannik LangtvedPallisgaardMD, PhDaMorten LockHansenMD, PhDa
doi : 10.1016/j.ahj.2021.10.182
Volume 244, February 2022, Pages 42-49
Cardiogenic shock complicating non-ST-segment elevation myocardial infarction: An 18-year study
SaraschandraVallabhajosyulaMD, MScaHuzefa M.BhopalwalaMBBSbPranathi R.SundaragiriMDcNakeyaDewaswalaMDdWisitCheungpasitpornMDeRajkumarDoshiMD, MPHfAbhiramPrasadMDgGurpreet S.SandhuMD, PhDgAllan S.JaffeMDgMalcolm R.BellMDgDavid R.HolmesJrMDg
doi : 10.1016/j.ahj.2021.11.002
Volume 244, February 2022, Pages 54-65
To evaluate the epidemiology and outcomes of non-ST-segment-elevation myocardial infarction-cardiogenic shock (NSTEMI-CS) in the United States.
Novel plasma biomarkers predicting biventricular involvement in arrhythmogenic right ventricular cardiomyopathy
DenizAkdisMDa#LiangChenMD, PhDb#Ardan M.SagunerMDaNingningZhangBSbJoannaGawineckaPhDcLanjaSalehMDcArnoldvon EckardsteinMDcdJieRenMDbChristian M.MatterMDaZhenliangHuMDbXiaoChenMSbFelix C.TannerMDaRobertMankaMDaKaiChenMD, PhDbCorinnaBrunckhorstMDaJiangpingSongMD, PhDb$FiratDuruMDad$
doi : 10.1016/j.ahj.2021.10.187
Volume 244, February 2022, Pages 66-76
Long-term mortality in asymptomatic patients with stable ischemic heart disease undergoing percutaneous coronary intervention
Anoop NKoshyMBBSabDiem TDinhBSc, PhDcJordanFulcherMBBS, PhDaAngela LBrennanRNcAlexandra CMurphyMBBSabStephen JDuffyMBBS, PhDcdChristopher MReidPhDcAndrew EAjaniMBBS, MDbcdMelanieFreemanMBBSefChinHiewMBBSgErnestoOqueliMDhOmarFarouqueMBBS, PhDabMatias BYudiMBBS, PhDabDavid JClarkMBBS, DMedSciabi
doi : 10.1016/j.ahj.2021.10.190
Volume 244, February 2022, Pages 77-85
Sinus of Valsalva Dimension and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation
DaijiroTomiiMDa#TaishiOkunoMDa#DikHegPhDbChristophGräniMD, PhDaJonasLanzMD, MScaFabienPrazMDaStefanStorteckyMDaStephanWindeckerMDaThomasPilgrimMD, MScaDavidReinekeMDc
doi : 10.1016/j.ahj.2021.11.004
Volume 244, February 2022, Pages 94-106
Association between economic and arrhythmic burden of paroxysmal atrial fibrillation in patients with cardiac implanted electronic devices
Derek S.ChewMD, MScabZhenLiPhDcBenjamin A.SteinbergMD, MHSdEmilyO'BrienPhDacJessicaPritchardPhDcT. JaredBunchMDdDaniel B.MarkMD, MPHaeManesh R.PatelMDacYelenaNabutovskyMSfMelissa A.GreinerMScJonathan P.PicciniMD, MHSace
doi : 10.1016/j.ahj.2021.11.006
Volume 244, February 2022, Pages 116-124
Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial
Benjamin D.Horne*†Joseph B.Muhlestein*‡Donald L.Lappé*‡Heidi T.May*Viet T.Le*§Tami L.Bair*DanielBabcock*DanielBride*Kirk U.Knowlton*¶Jeffrey L.Anderson*‡
doi : 10.1016/j.ahj.2021.11.001
Volume 244, February 2022, Pages 125-134
Bimodal distribution of atrial fibrillation burden in 3 distinct cohorts: What is ‘paroxysmal’ atrial fibrillation?
Benjamin A.SteinbergMD, MHSaZhenLiPhDbPeterShraderMScDerek S.ChewMDbcT. JaredBunchaDaniel B.MarkMD, MPHcdYelenaNabutovskyMSeRashmee U.ShahMD, MSaMelissa A.GreinerMSbJonathan P.PicciniMD, MHSbcd
doi : 10.1016/j.ahj.2021.11.012
Volume 244, February 2022, Pages 149-156
Burden of atrial fibrillation (AF), as a continuous measure, is an emerging alternative classification often assumed to increase linearly with progression of disease. Yet there are no descriptions of AF burden distributions across populations.
Cardiovascular risk factor profiles in North and South Indian and Pakistani Americans: The MASALA Study
Neha K.ReddyMD, MAab1VaidehiKaushalc1Alka M.KanayaMDdNamratha R.KandulaMD, MPHaeUnjali P.GujralPhD, MPHcNilay S.ShahMD, MPHef
doi : 10.1016/j.ahj.2021.10.115
Volume 244, February 2022, Pages 14-18
Real-world antithrombotic treatment variability in patients undergoing peripheral vascular intervention: Insights from the VQI registry
MeganLeeBSZain V.AhmedMD, MPHJiamingHuangMSQurat-ul-ainJelaniMDEdouardAboianMDPoghni A.Peri-OkonnyMDKim G.SmolderenPhDCarlosMena-HurtadoMD
doi : 10.1016/j.ahj.2021.10.186
Volume 244, February 2022, Pages 31-35
For those undergoing peripheral vascular interventions (PVI), guidelines indicate the use of dual antiplatelet therapy (DAPT) is reasonable (Class IIb), but recommendations have not reached the highest level of evidence. In the largest effort to date, we found that antithrombotic prescription was dominated by single antiplatelet therapy (SAPT) (51.4%) before PVI, which switched to DAPT (57.7%) following PVI, with some patients still remaining on no therapy (8%). High site variability in prescription rates (median odds ratio: 1.40, 95% confidence interval: 1.32, 1.48) was not much explained by patient and provider factors, revealing a need for the creation and integration of the newest trial data and for interventions at the health system or practice level to help physicians determine the optimal medical therapy following PVI.
Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study
VicenteArtola AritaMDaBernadet T.SantemaMDaRuben R.De WithMDaBao-OanhNguyenMDaDominikLinzMD, PhDbcdefUlrichSchottenMD, PhDcdIsabelle C.Van GelderMD, PhDaHarry JGM.CrijnsMD, PhDbcAdriaan A.VoorsMD, PhDaMichielRienstraMD, PhDa
doi : 10.1016/j.ahj.2021.10.183
Volume 244, February 2022, Pages 36-41
Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are 2 cardiovascular conditions that often coexist. Strain phases of both the left and right atria are more impaired in paroxysmal AF patients with HFpEF than those without HFpEF in spite of comparable global longitudinal strain of the left ventricle. Atrial function may differentiate paroxysmal AF patients with HFpEF from those without HFpEF.
Influenza vaccination among adults with cardiovascular disease in the United States: Results from the Behavioral Risk Factor Surveillance System 2018–2019
VarayiniPankayatselvanMDKenneth J.MukamalMD, MPH
doi : 10.1016/j.ahj.2021.09.004
Volume 244, February 2022, Pages 50-53
